Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Other Non-Current Assets (2016 - 2025)

Abeona Therapeutics (ABEO) has 15 years of Other Non-Current Assets data on record, last reported at $338000.0 in Q3 2025.

  • For Q3 2025, Other Non-Current Assets changed 0.0% year-over-year to $338000.0; the TTM value through Sep 2025 reached $338000.0, changed 0.0%, while the annual FY2024 figure was $96000.0, 71.6% down from the prior year.
  • Other Non-Current Assets reached $338000.0 in Q3 2025 per ABEO's latest filing, roughly flat from $338000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $5.9 million in Q4 2021 and bottomed at $96000.0 in Q4 2024.
  • Average Other Non-Current Assets over 5 years is $1.6 million, with a median of $338000.0 recorded in 2022.
  • The widest YoY moves for Other Non-Current Assets: up 504.21% in 2022, down 94.26% in 2022.
  • A 5-year view of Other Non-Current Assets shows it stood at $5.9 million in 2021, then plummeted by 94.26% to $338000.0 in 2022, then changed by 0.0% to $338000.0 in 2023, then tumbled by 71.6% to $96000.0 in 2024, then skyrocketed by 252.08% to $338000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $338000.0 in Q3 2025, $338000.0 in Q2 2025, and $338000.0 in Q1 2025.